Table 3. Disease-free and overall survival analyses according to MMP-9 levels.

Survival	Univariatea	Multivariate b	HR	95% CI
Disease-free survival
MMP-9 (low vs. high)	0.001	0.004	10.901	2.124	55.950
T stage (1 or 2 vs. 3)	0.649	0.201	4.477	0.449	44.641
N stage (0, 1 or 2 vs. 3)	0.147	0.122	3.393	0.720	15.989
Histologic grade (1 or 2 vs. 3)	0.039	0.615	1.429	0.356	5.740
Lymphatic invasion (negative vs. positive)	0.515	0.198	0.407	0.104	1.598
Perineural invasion (negative vs. positive)	0.013	0.023	4.181	1.215	14.386
ER/PR (positive vs. negative)	0.05	0.342	1.985	0.483	8.164
HER2 (negative vs. positive)	0.105	0.354	1.803	0.519	6.263
Overall survival
MMP-9 (low vs. high)	0.011	0.011	3.720	1.354	10.221
T stage (1 or 2 vs. 3)	<0.001	0.002	5.894	1.926	18.034
N stage (0, 1 or 2 vs. 3)	<0.001	0.002	6.047	1.975	18.516
Histologic grade (1 or 2 vs. 3)	<0.001	0.690	1.273	0.389	4.170
Lymphatic invasion (negative vs. positive)	<0.001	0.276	2.125	0.547	8.254
Perineural invasion (negative vs. positive)	0.015	0.106	2.203	0.845	5.744
ER/PR (positive vs. negative)	0.003	0.364	1.693	0.543	5.277
HER2 (negative vs. positive)	<0.001	0.016	3.487	1.264	9.617

T and N stages are according to the American Joint Committee on Cancer, 8^th edition.

ER/PR, estrogen receptor/progesterone receptor; HER2, human epithelial growth factor receptor 2

^aLog rank test.

^bCox proportional hazards model.

Bold indicates p < 0.05.